Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid.
Thirty-four patients with myelodysplastic syndromes, 23 men and 11 women, aged between 47 and 80 years, with all types of myelodysplastic syndromes were treated with 13-cis-retinoic acid. The dose of retinoic acid ranged between 10 and 60 mg/m2/daily and was administered in combination with vitamin E to diminish side effects. The duration of treatment was 3 months to 5 years. Partial remission was achieved in 4 patients, 1 with RA type, 2 with RAEB and 1 with CMML. Survival ranged from 1 to 5 years. Patients who received retinoic acid developed mild side effects. In conclusion, the administration of 13-cis-retinoic acid improves the hematological picture in a small number of MDS patients (11.7%).
Bourantas
K L
KL
Department of Internal Medicine, University of Ioannina, Greece.
Tsiara
S
S
Christou
L
L
D000368:Aged; D000753:Anemia, Refractory / Q000188:drug therapy / Q000401:mortality; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013997:Time Factors; D014810:Vitamin E / Q000627:therapeutic use
D014810:Vitamin E; D015474:Isotretinoin